Developers of Global Infection Control Technology, AsepticSure, Secure Top-Level Management Expertise in Bid to Earn Gold Standard for Disinfection, Worldwide.
San Francisco, California, June 7, 2012. Medizone International, Inc. (The Company) (MZEI:OB) (MZEI:QB) announced today that effective immediately, leading Canadian infection control expert, Dr Dick Zoutman, and Californian management consultant, Mr. Glen Balzer, will join its management team. The Company views this double-acquisition as a massive boost to its corporate strength as it readies itself for dramatic growth into the world arena of infection control.
Dr Michael Shannon, President of Medizone International, quoted Colin Powell who said,
“Endeavors succeed or fail because of the people involved. Only by attracting the best people will you accomplish great deeds.”
“That is exactly what we are now doing” stated Dr Shannon, “By attracting two of the most impressively qualified people on the continent we are creating the foundation for a team that will see our hospital disinfection technology, AsepticSure, become the gold standard for disinfection, worldwide, within the next 12 – 18 months.”
Although Dr Zoutman has worked as a consultant with Medizone for over three years, he has accepted the role as Chief Medical Officer. In this new role, as well as continuing to provide direct microbiology support to Dr Shannon, Dr Zoutman will also report to both the President and the Chief Executive Officer with responsibilities including:
- providing input into the design, planning, initiation and analysis of all beta test and post market surveillance programs worldwide.
- providing direct liaison with clinical investigators and maintaining professional awareness of Medizone’s many scientific accomplishments through the preparation of peer reviewed articles and the preparation of presentations at medical conferences.
Dr Zoutman’s appointment is also timely in that he is scheduled to deliver a scientific presentation at the upcoming Community and Hospital Infection Control Association Conference. This unique opportunity will bring to the attention of opinion leaders in this field, the fact that AsepticSure is 10,000 times more effective at killing pathogens than any cleaning process currently being used in North American hospitals.”
Complimenting Dr Zoutman’s expanded role is the appointment of Mr. Glen Balzer. Glen brings an enormous wealth of experience and expertise into the vital area of national and international sales and marketing channel development.
Asked about his role and the value he can add to the Company’s growth strategy, Mr. Balzer stated, “One of my first priorities is to establish relationships with sales channel partners that will leverage on the growing interest that AsepticSure is currently generating. Medizone will then focus on those markets that are taking hospital acquired infections most seriously. Within those markets, I plan to focus on market verticals that offer the greatest opportunity to initiate and develop revenue.”
Balzer went on to say, “With the dual opportunity to improve the health of millions of people while simultaneously helping health facilities save money, it will be easy to garner the attention of potential distributors and other sales channel partners. Our challenge will be to identify and engage with those partners that can forge into our most important markets.”
For press information on Medizone International, please contact:
Bruce Smeaton, Investor Relations, Medizone International, Inc.
T: 001-415-331-0202 E: firstname.lastname@example.org
Medizone International, Inc. is engaged in initial production of its modular design AsepticSure™ Decontamination Systems. Decontamination to the sterilization standard of >6 log (99.9999%) is obtainable within hospitals, airlines, cruise ships, long term care facilities, food processing plants, clean room manufacturing facilities, schools and other critical infrastructure. A government variant is being tested for bio-terrorism counter measures for building remediation.
This Press Release may contain certain forward looking statements that could involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company’s filings made with the Securities and Exchange Commission.
For more information, visit: www.medizoneint.com